Profil bibliographique

Thomas Baker

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

69Publications signalées

976Citations signalées

2Affiliations récentes

Institutions déclarées

Johnson & Johnson (United States)Janssen (Switzerland)

Domaines associés

Inflammatory Bowel DiseaseEosinophilic EsophagitisImmunodeficiency and Autoimmune DisordersAntibiotic Resistance in BacteriaChronic Lymphocytic Leukemia Research

Publications récentes

2025 conference-paperOpenAlex

Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 24 from the phase 3 ASTRO study

Ursula Seidler, M Long, Jessica R. Allegretti, Silvio Danese et autres

0 citationsZeitschrift für Gastroenterologie

2025 conference-abstractOpenAlex

P0608 Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis

B E Sands, Remo Panaccione, Silvio Danese, Julián Panés et autres

1 citationJournal of Crohn s and Colitis

2025 conference-abstractOpenAlex

OP10 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro et autres

13 citationsJournal of Crohn s and Colitis

Accès ouvert 2024 conference-abstractOpenAlex

P954 Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study

David T. Rubin, Bruce E. Sands, Gary R. Lichtenstein, Thomas Baker et autres

0 citationsJournal of Crohn s and Colitis

2023 conference-abstractOpenAlex

S842 Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn’s Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study

Brian G. Feagan, Scott D. Lee, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

0 citationsThe American Journal of Gastroenterology

2023 conference-abstractOpenAlex

S1035 Analysis of Baseline Characteristics Associated With Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients With Crohn’s Disease in the POWER Trial

Douglas C. Wolf, Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude et autres

0 citationsThe American Journal of Gastroenterology

2023 conference-abstractOpenAlex

S1073 Clinical Outcomes and Biomarker Normalization Response at Week 16 in Patients With Inadequate Response or Intolerance to Prior Biologics in the POWER Trial

Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

0 citationsThe American Journal of Gastroenterology

2023 conference-abstractOpenAlex

S903 Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

David T. Rubin, Bruce E. Sands, Gary R. Lichtenstein, Thomas Baker et autres

2 citationsThe American Journal of Gastroenterology

2023 articleOpenAlex

Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response during ustekinumab maintenance therapy: week 16 results from the phase 3b POWER trial

Stefan Schreiber, S. Lee, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

0 citationsZeitschrift für Gastroenterologie

2023 articleOpenAlex

1027 EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB REINDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIAL

Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

3 citationsGastroenterology

Accès ouvert 2023 articleOpenAlex

A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease

Matthieu Allez, Bruce E. Sands, Brian G. Feagan, Geert D’Haens et autres

11 citationsJournal of Crohn s and Colitis

2023 conference-abstractOpenAlex

P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial

S Schreiber, Sujin Lee, C. Janneke van der Woude, Ignacio Marín‐Jiménez et autres

12 citationsJournal of Crohn s and Colitis

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.